| Celgene is a global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Co.'s primary commercial stage products include: REVLIMID®, an oral immunomodulatory drug; POMALYST®/IMNOVID®, a proprietary, small molecule; OTEZLA®, an oral small-molecule inhibitor of phosphodiesterase 4 for cyclic adenosine monophosphate; ABRAXANE®, a solvent-free chemotherapy product; and VIDAZA®, a pyrimidine nucleoside analog. In addition, Co. provides other product sales and licensing arrangements. We show 39 historical shares outstanding datapoints in our coverage of CELG's shares outstanding history.|
Understanding the changing numbers of CELG shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CELG versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CELG by allowing them to research CELG shares outstanding history
as well as any other stock in our coverage universe.